BioSpace News Archive

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that its Board of Directors has authorized the repurchase of up to $40 million of shares of Catalyst’s outstanding common stock.

Rezolute, Inc.(“Rezolute” or “the Company”) (Nasdaq: RZLT) today presented positive results of a Phase 2a study of RZ358 in patients with post-gastric bypass hypoglycemia (PGBH), as well as results of a pharmacologic model of the drug candidate, at the Endocrine Society’s Annual Meeting, ENDO 2021, held virtually from March 20 through March 23

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it will be added to the Russell 2000® Index effective March 22, 2021, as part of its quarterly initial public offering (IPO) additions.

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company has signed an agreement to form a joint venture with Genesis MedTech Group

Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced completion of patient recruitment in its Phase 1 clinical trial of DARE-HRT1 being conducted through its wholly owned subsidiary in Australia. DARE-HRT1 is a novel intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period. It is being developed for the treatment of vasomotor s

- Company can file New Drug Application (NDA) for Wakix, a narcolepsy drug approved in the U.S. and Europe, using overseas clinical trial data - - The new alliance with CARD, announced during Sleep Awareness Week 2021, further empowers Citrine to build the first rare disease ecosystem in China -

First-of-its-kind medium resembles the natural cellular environment found in the human body for more physiologically relevant cell culture models

JAR of Hope (https://jarofhope.org), a foundation researching a cure for a fatal children’s disease called Duchenne muscular dystrophy, has just received good news. The Food & Drug Administration has approved an IND (Investigational New Drug) application to begin clinical trials of a compound called JAR914

Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company.

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced positive preclinical data demonstrating that GLP-1R antibodies identified from its proprietary G-protein coupled receptor (GPCR)